Format

Send to

Choose Destination
See comment in PubMed Commons below
Drug Discov Today. 2012 May;17(9-10):496-504. doi: 10.1016/j.drudis.2011.11.002. Epub 2011 Nov 18.

Therapeutic potential for novel ultra long-acting β2-agonists in the management of COPD: biological and pharmacological aspects.

Author information

1
Department of Internal Medicine, University of Brescia, 1st Divisione di Medicina, Az Spedali Civili, Pzza Spedali Civili 1, 25100 Brescia, Italy. malerba@med.unibs.it

Abstract

Chronic obstructive pulmonary disease (COPD) is characterised by progressive airflow limitation. In moderate-to-severe COPD, long-acting bronchodilators are the basis of therapy. Inhaled long-acting β(2)-agonists (LABAs) are used for the treatment of COPD. LABAs have been in use since the 1990s enabling persistent bronchodilation for 12 hours; however, sustained bronchodilation is desirable. Compared with twice-daily LABAs, new LABAs with ultra-long duration (ultra-LABAs) could provide improvements in efficacy and compliance with fast onset of action, 24-hour bronchodilation and a good safety profile. Several novel ultra-LABAs showing once-daily delivery profiles are in development. In this article, we discuss these novel agents' properties and clinical trials of their efficacy and safety, including the only licensed ultra-LABA, indacaterol.

PMID:
22119310
DOI:
10.1016/j.drudis.2011.11.002
[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science
    Loading ...
    Support Center